关于在治疗风湿性关节炎时使用甲醇的最新情况
R Matloob1, Z Althanoon2, S Algburi1
11lbn -Sina Teaching Hospital, Nineveh Health Directorate, Mosul, Iraq.
Georgian medical news
|April 12, 2024
概括
类风湿性关节炎 (RA) 是一种自身免疫性疾病,导致关节炎症和损伤. 管理包括药物治疗和生活方式的改变,以减轻心脏病等风险.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 内部医学 内部医学
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,其特征是膜持续炎症.
- 未经治疗的RA会导致渐进的关节损伤,疼痛,降低生活质量和增加死亡率.
- 影响大约1%的人口,RA通常在生命的第三到第五十年之间出现,女性患病率更高.
研究的目的:
- 提供有关类风湿性关节炎 (RA) 的全面概述.
- 讨论目前的RA治疗方法,包括药理和非药理方法.
- 强调在RA患者中管理心血管疾病相关风险因素的重要性.
主要方法:
- 对现有关于类风湿性关节炎的文献的审查.
- 分析当前的治疗指南和治疗策略.
- 重点是改变生活方式和风险因素管理.
主要成果:
- 关节炎需要复杂的,多阶段的治疗方案.
- 非药物干预,包括患者教育,物理治疗和职业治疗,至关重要.
- 由于缺血性心脏病风险增加,管理吸烟,高血压,高脂和肥胖等心血管风险因素至关重要.
结论:
- 有效的RA管理需要药物和全面的非药物治疗策略的结合.
- 专注于生活方式修改的综合护理对于改善患者的治疗结果和减少并发症至关重要.
- 需要继续进行研究和临床试验,以优化RA治疗并最大限度地降低相关健康风险.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
161
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
161
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
136
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
136
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Phase II Reactions: Methylation Reactions
181
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
181
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138


